Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05266430 · ClinicalTrials.gov registry record
Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)
A clinical trial, sponsored by Aura Biosciences.
- Terminated
- Registry status
- 2
- Enrollment target
NCT05266430: Clinical Trial study, sponsored by Aura Biosciences.
NCT05266430 is a clinical trial that was terminated before completion, run by Aura Biosciences. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05266430 was terminated before completion, sponsored by Aura Biosciences.
- TERMINATED
- Registry status
- 2 participants
- Enrollment target
Study Summary
This is a prospective multicenter, group-matched study of patients with primary indeterminate lesions or choroidal melanoma who receive treatment with belzupacap sarotalocan (bel-sar; AU-011) and patients who are planned to receive standard of care (SOC) treatment with plaque radiotherapy (plaque) to compare the visual outcomes of AU-011 and plaque radiotherapy.
Primary Outcome
Change from baseline in logMAR visual acuity score at 5 years.
Interventions
- OTHER Standard of Care
- DRUG AU-011
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2022-04-14 |
| Est. Completion | 2023-04-20 |
Why NCT05266430 stopped before completion
NCT05266430 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 2 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Standard of Care is the first listed.
NCT05266430 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05266430 about?
NCT05266430 is a clinical study titled "Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)". This is a prospective multicenter, group-matched study of patients with primary indeterminate lesions or choroidal melanoma who receive treatment with belzupacap sarotalocan (bel-sar; AU-011) and patients who are planned to receive standard of care (SOC) treatment with plaque radiotherapy (plaque) t...
What is the current status of trial NCT05266430?
This trial is currently terminated. The enrollment target is 2 participants. The study started on 2022-04-14. Estimated completion is 2023-04-20.
What interventions are being tested in trial NCT05266430?
The interventions under investigation include: Standard of Care (OTHER), AU-011 (DRUG).
Who is sponsoring clinical trial NCT05266430?
This trial is sponsored by Aura Biosciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI